Market Overview:
The global nicardipine hydrochloride injection market is expected to register a CAGR of 5.5% during the forecast period, 2018-2030. The growth in the market can be attributed to factors such as rising prevalence of hypertension and increasing number of product approvals for nicardipine hydrochloride injection. Based on type, the global nicardipine hydrochloride injection market has been segmented into 20 mg / 200 mL and 40 mg / 200 mL. The 20 mg / 200 mL segment is expected to account for a larger share of the market in 2018, owing to its lower price point as compared to 40 mg / 200 mL products. However, the 40 mg / 200 ml segment is projected to grow at a higher CAGR during the forecast period due its greater efficacy in treating hypertension than 20 mg/200 ml products. Based on application, the global nicardipine hydrochloride injection market has been divided into hospital use, clinic use and recovery center use. The hospital use segment is estimated to account for majority share of the overall market in 2018 owing high utilization rates across hospitals worldwide coupled with rising incidence rate of hypertension globally .
Product Definition:
Nicardipine Hydrochloride Injection is a calcium channel blocker used to treat high blood pressure and chest pain.
20 mg / 200 mL:
20 mg / 200 mL, it's usage and growth factor in Nicardipine Hydrochloride Injection market is driven by the rise in chronic diseases such as cardiovascular disorders, diabetes mellitus. The other major factors that are driving 20 mg / 200 mL, it's usage and growth factor include an increase in the number of geriatric population and a growing number of patients suffering from hypertension.
40 mg / 200 mL:
40 mg / 200 mL is a concentration used for the treatment of heart failure and to reduce the frequency of cardiac arrhythmias. It is also used as an anti-epileptic drug, which means it helps prevent seizures. The medicine has no effect on pain or cold sensitivity and does not relieve any other symptoms apart from those caused by heart failure or epilepsy.
Application Insights:
The hospital application segment led the global nicardipine hydrochloride injection market in 2017 and is projected to witness significant growth over the forecast period. The increasing prevalence of cardiovascular diseases, growing geriatric population, and rising number of hospital admissions are some of the factors that are expected to drive demand for this drug in hospitals during the forecast period.
Clinic applications accounted for a share of 29% in 2017 owing to increased usage as an anti-arrhythmic agent along with other drugs such as amiodarone or sotalol. This combination therapy is used for treating arrhythmias caused due to various underlying causes such as electrolyte imbalance, hypoxia, hypercapnia & acidosis. In addition, it also finds application in non-electrophysiology cardiac disorders (NECD).
Regional Analysis:
North America dominated the global Nicardipine Hydrochloride Injection market in 2017. The presence of well-established healthcare infrastructure, high patient awareness levels coupled with relatively higher healthcare expenditure levels in this region are some factors responsible for its large share.
Asia Pacific is expected to be the fastest growing regional market over the forecast period owing to rising product demand and increasing number of hospitals & clinics as well as recovery centers throughout this region. Increasing geriatric population, improving lifestyle conditions and rapid economic development are also driving growth in this region. Moreover, government initiatives encouraging people to opt for non-surgical procedures such as acupuncture and Chinese herbal medicine will boost industry penetration rates over the forecast period.
Growth Factors:
- Increasing incidence of cardiovascular diseases: The increasing incidence of cardiovascular diseases is one of the key growth drivers for the Nicardipine Hydrochloride Injection market. According to a study by the World Health Organization, it was found that in 2012, around 17.5 million people died from CVDs, which accounted for 31% of all global deaths. This number is expected to rise to 23 million by 2030. This growing prevalence of CVDs is expected to drive demand for Nicardipine Hydrochloride Injection products over the forecast period.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to be a major driver for the Nicardipine Hydrochloride Injection market over the forecast period. As per United Nations estimates, the number of people aged 60 years or above will exceed 2 billion by 2050, accounting for nearly one-third of world’s population. This rising geriatric population is more susceptible to developing heart conditions and other chronic diseases, which will lead to an increase in demand for Nicardipine Hydrochloride Injection products in coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
Nicardipine Hydrochloride Injection Market Research Report
By Type
20 mg / 200 mL, 40 mg / 200 mL
By Application
Hospital, Clinic, Recovery Center
By Companies
Baxter, Hikma, Mylan, Sun Pharma, Chiesi, Wockhardt, DMS Pharmaceutical, Sandoz, Navinta, Teva, Shanghai Furen Medicine
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Nicardipine Hydrochloride Injection Market Report Segments:
The global Nicardipine Hydrochloride Injection market is segmented on the basis of:
Types
20 mg / 200 mL, 40 mg / 200 mL
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Recovery Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Hikma
- Mylan
- Sun Pharma
- Chiesi
- Wockhardt
- DMS Pharmaceutical
- Sandoz
- Navinta
- Teva
- Shanghai Furen Medicine
Highlights of The Nicardipine Hydrochloride Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 20 mg / 200 mL
- 40 mg / 200 mL
- By Application:
- Hospital
- Clinic
- Recovery Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nicardipine Hydrochloride Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nicardipine hydrochloride injection is a medication used to treat pain and inflammation. It is also used to reduce the risk of heart attack or stroke.
Some of the key players operating in the nicardipine hydrochloride injection market are Baxter, Hikma, Mylan, Sun Pharma, Chiesi, Wockhardt, DMS Pharmaceutical, Sandoz, Navinta, Teva, Shanghai Furen Medicine.
The nicardipine hydrochloride injection market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nicardipine Hydrochloride Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nicardipine Hydrochloride Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nicardipine Hydrochloride Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nicardipine Hydrochloride Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nicardipine Hydrochloride Injection Market Size & Forecast, 2020-2028
4.5.1 Nicardipine Hydrochloride Injection Market Size and Y-o-Y Growth
4.5.2 Nicardipine Hydrochloride Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 20 mg / 200 mL
5.2.2 40 mg / 200 mL
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Recovery Center
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nicardipine Hydrochloride Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nicardipine Hydrochloride Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 20 mg / 200 mL
9.6.2 40 mg / 200 mL
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Recovery Center
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 20 mg / 200 mL
10.6.2 40 mg / 200 mL
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Recovery Center
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 20 mg / 200 mL
11.6.2 40 mg / 200 mL
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Recovery Center
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 20 mg / 200 mL
12.6.2 40 mg / 200 mL
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Recovery Center
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 20 mg / 200 mL
13.6.2 40 mg / 200 mL
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Recovery Center
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nicardipine Hydrochloride Injection Market: Competitive Dashboard
14.2 Global Nicardipine Hydrochloride Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter
14.3.2 Hikma
14.3.3 Mylan
14.3.4 Sun Pharma
14.3.5 Chiesi
14.3.6 Wockhardt
14.3.7 DMS Pharmaceutical
14.3.8 Sandoz
14.3.9 Navinta
14.3.10 Teva
14.3.11 Shanghai Furen Medicine
